CAM ProgramFourth generation CAM program

Fourth generation CAMs are being developed for the treatment of HBV

Derived from a novel chemical scaffold, capsid assembly modulators (CAMs) have shown strong in vitro and in vivo activity in a transgenic mouse model of hepatitis B virus (HBV) infection.1

Early in vivo data point to a differentiated mechanism of action (MOA) which prevents accumulation of empty capsids, unlike most CAMs, and potentially provides for a more targeted, productive clearance by the immune system.1

ATI-1428 and ATI-1645 have been identified as fourth generation sub-nM potent compounds from a novel series of class II CAMs.1

Derived from a novel chemical scaffold, both CAMs show safe and potent in vitro and in vivo activity, as well as excellent pharmacokinetic and developability profiles.1

Early in vivo data point to a differentiated MOA that prevents accumulation of empty capsids in the hepatocellular cytoplasm, unlike most CAMs, and potentially provides for a more targeted, productive clearance by the immune system.1

ATI-1428 and ATI-1645 display strong antiviral activity against naturally occurring variants and low EC50 shift against variants associated with resistance to past and current CAMs​.1

Why fourth generation CAMs?

Fourth generation CAMs result in more potent viral suppression than earlier generations, as measured by 2 key markers of HBV replication1

ATI-1428 and ATI-1645 deeply inhibit HBV replication and prevent cccDNA establishment without causing liver damage.1

Our CAMs have the potential to synergize with our ASPIN, ATI-2173, and target different stages of the HBV life cycle.1

Watch CAM MOA Video

CAM program selected for unique mechanism of action1

  • Traditional CAMs being developed by others induce retention of hepatitis B core antigen (HBcAg), while Antios’ proprietary novel CAMs (ATI-1428 and ATI-1645) do not1
  • The retention of HBcAg empty capsid could be a clinical safety liability and a decoy for functional immune-based clearance1
  • Competitor CAMs have on- and off-treatment ALT flares in their clinical programs1

The CAM program is the next step in our mission to create a world without HBV.

Find out more

Reference: 1. Data on file. Antios Therapeutics, Doylestown, PA.

Improving lives through the treatment of HBV About our therapies